Brukinsa showed a higher estimated three-year progression-free survival rate—89.2% compared to 78.9%—even when compared to a combination therapy. This highlights how much pharmacokinetic properties and sustained BTK inhibition matter at the cellular level.
Brukinsa (Zanubrutinib) and Calquence (Acalabrutinib) are both next-generation BTK inhibitors used to treat B-cell malignancies like CLL and Mantle Cell Lymphoma. While they share a similar mechanism of action by targeting the Bruton's tyrosine kinase protein, they differ in their chemical structures and clinical trial data. Doctors often compare these two medications based on their specific efficacy rates and side effect profiles to determine which is the most appropriate choice for an individual patient's treatment plan.
BTK inhibitors like Brukinsa and Calquence work by blocking the activity of the Bruton's tyrosine kinase enzyme, which is essential for the survival and proliferation of cancerous B-cells. By inhibiting this pathway, these drugs help slow down or stop the progression of Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma. These targeted therapies represent a significant advancement over traditional chemotherapy, offering a more precise approach to managing these specific types of blood cancers.
Both Zanubrutinib (Brukinsa) and Acalabrutinib (Calquence) have shown high levels of efficacy in clinical trials for the treatment of CLL. The choice between them often depends on the specific results of head-to-head studies and the patient's underlying health conditions. Medical professionals evaluate factors such as progression-free survival and the duration of response when comparing these two BTK inhibitors. Ongoing research continues to provide data on how these medications perform over long-term use in diverse patient populations.
From Columbia University alumni built in San Francisco
"Instead of endless scrolling, I just hit play on BeFreed. It saves me so much time."
"I never knew where to start with nonfiction—BeFreed’s book lists turned into podcasts gave me a clear path."
"Perfect balance between learning and entertainment. Finished ‘Thinking, Fast and Slow’ on my commute this week."
"Crazy how much I learned while walking the dog. BeFreed = small habits → big gains."
"Reading used to feel like a chore. Now it’s just part of my lifestyle."
"Feels effortless compared to reading. I’ve finished 6 books this month already."
"BeFreed turned my guilty doomscrolling into something that feels productive and inspiring."
"BeFreed turned my commute into learning time. 20-min podcasts are perfect for finishing books I never had time for."
"BeFreed replaced my podcast queue. Imagine Spotify for books — that’s it. 🙌"
"It is great for me to learn something from the book without reading it."
"The themed book list podcasts help me connect ideas across authors—like a guided audio journey."
"Makes me feel smarter every time before going to work"
From Columbia University alumni built in San Francisco
